Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BA3181
- Development stage
- Discontinued
- Lead developer
- BioAtla
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
BA3181 is a novel conditionally active biologic (CAB) antibody-drug conjugate (ADC) designed to target the Epithelial Cell Adhesion Molecule (EpCAM). Developed by BioAtla, BA3181 utilizes proprietary CAB technology, which allows the antibody to bind to its target preferentially under the unique conditions of the tumor microenvironment (such as low pH) while remaining inactive in normal physiological conditions. This conditional activation is intended to improve the safety profile and therapeutic index of EpCAM-targeted therapy, which has historically been limited by off-target toxicity in healthy epithelial tissues. EpCAM is highly expressed in a variety of solid tumors and cancer stem cells, making it an attractive target for ADC-mediated delivery of cytotoxic agents. Although BA3181 entered Phase 1 clinical trials for advanced solid tumors, the program was subsequently terminated by the developer to prioritize other assets in their pipeline.
- Other names
- CAB-EpCAM-ADC
02
Targets
EPCAM (Epithelial cell adhesion molecule)
Beyond the preview
Go deeper on BA3181.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BA3181.